InsiderTrades.com logo
Bill Gates’s Next Big AI Bet: Stargate
From Brownstone Research   |   Ad
In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.
I believe we are about to do it again with this new AI project called Stargate
Mark Paul Lappe net worth and biography
  • Phone
  • Email
  • Website

Mark Lappe Biography and Net Worth

Founder of Inhibrx
Mr. Lappe co-founded Inhibrx in 2010 and has served as Chief Executive Officer since our inception. He also serves as the Chairman of our board of directors. Mr. Lappe has extensive expertise in the biotechnology industry with over 30 years of experience in executive management, investment management, and executive recruiting, having built the executive teams of over 40 start-up biotechnology and medical device companies. Prior to founding Inhibrx, Mr. Lappe was the founder and Managing Partner of Efficacy Biotech Fund, a fund focused on strategic investment in public biotechnology companies.

How old is Mark Paul Lappe?

Mr. Lappe is currently 57 years old. There are 3 older executives and no younger executives at Inhibrx. Learn More on Mark Paul Lappe's age.

How do I contact Mark Paul Lappe?

The corporate mailing address for Mr. Lappe and other Inhibrx executives is 11025 N. TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. Inhibrx can also be reached via phone at 858-795-4220 and via email at [email protected]. Learn More on Mark Paul Lappe's contact information.

Has Mark Paul Lappe been buying or selling shares of Inhibrx?

Mark Paul Lappe has not been actively trading shares of Inhibrx over the course of the past ninety days. Learn More on Mark Paul Lappe's trading history.

Who are Inhibrx's active insiders?

Inhibrx's insider roster includes Brendan Eckelman (Insider), Jeffrey Jensen (EVP & Chief Clinical Devel. Officer), and Mark Lappe (Founder). Learn More on Inhibrx's active insiders.

Are insiders buying or selling shares of Inhibrx?

During the last twelve months, Inhibrx insiders bought shares 8 times. They purchased a total of 163,228 shares worth more than $2,627,085.64. During the last twelve months, insiders at the sold shares 1 times. They sold a total of 300,000 shares worth more than $10,290,000.00. The most recent insider tranaction occured on September, 16th when CEO Mark Lappe bought 13,037 shares worth more than $223,323.81. Insiders at Inhibrx own 22.2% of the company. Learn More about insider trades at Inhibrx.

Information on this page was last updated on 9/16/2024.

Mark Paul Lappe Insider Trading History at Inhibrx

See Full Table

Mark Paul Lappe Buying and Selling Activity at Inhibrx

This chart shows Mr. Mark Paul Lappe's buying and selling at Inhibrx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Inhibrx Company Overview

Inhibrx logo
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
Read More

Today's Range

Now: $13.83
Low: $12.25
High: $14.77

50 Day Range

MA: $15.75
Low: $13.83
High: $17.49

2 Week Range

Now: $13.83
Low: $10.80
High: $18.95

Volume

178,264 shs

Average Volume

51,015 shs

Market Capitalization

$200.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Bill Gates’s Next Big AI Bet: Stargate
From Brownstone Research   |   Ad
In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.
I believe we are about to do it again with this new AI project called Stargate